Animal Models Core
动物模型核心
基本信息
- 批准号:10024664
- 负责人:
- 金额:$ 61.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAirway DiseaseAnimal ModelAnimalsBiliary cirrhosisBiologicalBloodBronchoalveolar Lavage FluidCaringCell Culture TechniquesConsultationsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDiseaseDisease ProgressionEnsureExocrine pancreasFamily suidaeFerretsGallbladderGenesGenetic EngineeringGoalsHarvestHumanHuman ResourcesInfectionInflammationIntestinal ObstructionIntestinesKnowledgeLiverLungMale Genital OrgansMeasuresMicrobiologyModelingMolecularMonitorMorbidity - disease rateMouse StrainsMutationNeonatalOrganPancreasPancreatic DiseasesPathogenesisPathologyPatientsPreventionProductionProgram Research Project GrantsPulmonary Cystic FibrosisResearch PersonnelSamplingSinusStructural defectSweat GlandsTimeVas deferens structureanimal carecystic fibrosis mousedisease-causing mutationexperiencehealth assessmentimprovedin vitro Modelmortalityprogramsreproductive tractsample collectionsmall moleculesuccess
项目摘要
CORE C – ANIMAL MODELS
PROJECT SUMMARY
Cystic fibrosis (CF) is a common autosomal recessive disease caused by mutations in the gene encoding the
cystic fibrosis transmembrane conductance regulator (CFTR). CF affects multiple organs, including lungs,
pancreas, intestine, liver, sweat glands, gallbladder, and the male genital tract. Airway infection and
inflammation currently cause most of the morbidity and mortality. Although several therapies have improved the
lives of patients, current treatments are inadequate and CF remains a lethal disease. Our knowledge about the
pathogenesis of the disease, its progression, and the state of the neonatal lung is inadequate. These gaps in
our knowledge have hindered attempts to develop better treatments and preventions for CF lung disease. A
major impediment to addressing these issues had been limitations of animal models. Although mouse strains
carrying null and missense CFTR mutations have made enormous contributions, CF mice do not develop the
airway or pancreatic disease typically found in humans. We have generated CF ferrets and pigs that replicate
many of the key features of human CF disease including intestinal obstruction, exocrine pancreatic destruction,
micro-gallbladder, vas deferens abnormalities, focal biliary cirrhosis, congenital airway structural abnormalities,
and airway and sinus infection with time. The goals of the Animal Models Core will be: (1) To provide Program
investigators with non-CF and CF ferrets and pigs so that they can successfully complete their project aims. (2)
To build new genetically engineered CF ferret models that express CFTR in a regulated fashion. (3) To assist
projects in carrying out small molecule delivery, the harvesting of biologic samples from live animals (e.g.,
bronchoalveolar lavage fluid, blood, and microbiological samples), and the care and analysis of study animals.
(4) To assist projects in record keeping and coordinate animal usage among projects. The Animal Models Core
will function seamlessly through already established interactions with the Project Leaders, Pathology Core, In Vitro
Models and Cell Culture Core, and the Administrative Core. The success of the Animal Models Core is ensured
because of the commitment, experience, and expertise that the personnel bring to the Core.
核心C - 动物模型
项目摘要
囊性纤维化(CF)是由编码基因突变引起的常见常染色体隐性疾病
囊性纤维化跨膜电导调节剂(CFTR)。 CF影响包括肺在内的多个器官
胰腺,肠,肝脏,汗腺,胆囊和雄性生殖道。气道感染和
目前,炎症会导致大部分发病率和死亡率。尽管几种疗法改善了
患者的生活,目前的治疗不足,CF仍然是致命的疾病。我们对
疾病的发病机理,其进展和新生儿肺的状态不足。这些差距
我们的知识阻碍了为CF肺部疾病开发更好的治疗方法和预防措施的尝试。一个
解决这些问题的主要障碍是动物模型的局限性。虽然小鼠菌株
携带无效和错义CFTR突变已做出了巨大的贡献,CF小鼠不会发展
在人类中通常发现的气道或胰腺疾病。我们产生了复制的CF雪貂和猪
人类CF疾病的许多关键特征,包括肠反应,外分泌胰腺破坏,
微型加仑,VAS延期异常,局灶性胆道肝硬化,先天性气道结构异常,
随着时间的流逝,气道和鼻窦感染。动物模型核心的目标将是:(1)提供程序
非CF和CF雪貂和猪的研究人员可以成功完成项目的目标。 (2)
建立新的一般工程的CF雪貂模型,以受管制的方式表达CFTR。 (3)协助
进行小分子递送的项目,从活体动物中收集生物样品(例如
支气管肺泡灌洗液,血液和微生物样品)以及研究动物的护理和分析。
(4)协助项目在项目之间进行记录和协调动物使用情况。动物模型核心
通过已经建立的与项目领导者,病理核心,体外建立的互动,将无缝发挥作用
模型和细胞培养核心以及行政核心。确保动物模型核心的成功
由于人事带来的承诺,经验和专业知识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID A STOLTZ其他文献
FATAL LUNG INJURY SECONDARY TO TRIMETHOPRIM-SULFAMETHOXAZOLE
- DOI:
10.1016/j.chest.2023.07.1615 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:
- 作者:
HALEY PYSICK;DAVID A STOLTZ - 通讯作者:
DAVID A STOLTZ
DAVID A STOLTZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID A STOLTZ', 18)}}的其他基金
Climate Change and Lung Health Training Program
气候变化与肺部健康培训计划
- 批准号:
10556149 - 财政年份:2023
- 资助金额:
$ 61.06万 - 项目类别:
Testing the Contributions of Airway Submucosal Glands and Surface Epithelia to Lung Health
测试气道粘膜下腺和表面上皮对肺部健康的贡献
- 批准号:
10597111 - 财政年份:2022
- 资助金额:
$ 61.06万 - 项目类别:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
气道碱化和重新利用氨丁三醇作为囊性纤维化的治疗方法
- 批准号:
10155587 - 财政年份:2017
- 资助金额:
$ 61.06万 - 项目类别:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
气道碱化和重新利用氨丁三醇作为囊性纤维化的治疗方法
- 批准号:
9289053 - 财政年份:2017
- 资助金额:
$ 61.06万 - 项目类别:
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis
气道碱化和重新利用氨丁三醇作为囊性纤维化的治疗方法
- 批准号:
9918957 - 财政年份:2017
- 资助金额:
$ 61.06万 - 项目类别:
Paraoxonase-2 S311C Polymorphism Alters Glycosylation and Lactonase Activity
Paraoxonase-2 S311C 多态性改变糖基化和内酯酶活性
- 批准号:
8110743 - 财政年份:2010
- 资助金额:
$ 61.06万 - 项目类别:
相似国自然基金
COPD气道黏液高分泌的CFTR调控机制及全真一气汤对其影响研究
- 批准号:81774103
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:面上项目
受肺内微生物影响的NODAL分子在气道高反应性疾病中的作用及分子机制的研究
- 批准号:31670121
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
Notch信号通路影响气道平滑肌细胞合成基质金属蛋白酶12以促进COPD的机制探讨
- 批准号:81300031
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
NADPH氧化酶和线粒体UCP2蛋白影响人气道平滑肌细胞氧化/抗氧化平衡的作用及机制
- 批准号:81360004
- 批准年份:2013
- 资助金额:49.0 万元
- 项目类别:地区科学基金项目
慢性阻塞性肺疾病中DNA加合物对气道表遗传学和慢性炎症影响的研究
- 批准号:81070036
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 61.06万 - 项目类别:
The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)
睡眠呼吸暂停加慢性阻塞性肺病(重叠综合征)对心血管的影响
- 批准号:
10733384 - 财政年份:2023
- 资助金额:
$ 61.06万 - 项目类别:
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
SARS-CoV-2 感染对患有和不患有哮喘的儿童呼吸道病毒免疫反应的影响
- 批准号:
10568344 - 财政年份:2023
- 资助金额:
$ 61.06万 - 项目类别:
Gene regulatory networks in early lung epithelial cell fate decisions
早期肺上皮细胞命运决定中的基因调控网络
- 批准号:
10587615 - 财政年份:2023
- 资助金额:
$ 61.06万 - 项目类别:
A Low-Cost Wearable Connected Health Device for Monitoring Environmental Pollution Triggers of Asthma in Communities with Health Disparities
一种低成本可穿戴互联健康设备,用于监测健康差异社区中哮喘的环境污染诱因
- 批准号:
10601615 - 财政年份:2023
- 资助金额:
$ 61.06万 - 项目类别: